抗体疗法-话题@MedSci

#抗体疗法#

26篇内容 | 1641人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1575868, encodeId=70c215e5868d9, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=FDA授权礼来公司的第二个COVID-19抗体疗法bebtelovimab, objectType=article, longId=295530, objectId=2e9829553018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e9829553018, replyNumber=0, likeNumber=98, createdTime=2022-02-14, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e9829553018, moduleTitle=FDA授权礼来公司的第二个COVID-19抗体疗法bebtelovimab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e9829553018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575867, encodeId=0c4a15e586713, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=在需求激增的情况下，葛兰素史克和Vir提高了COVID-19抗体疗法Sotrovimab的产量, objectType=article, longId=294567, objectId=286329456e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286329456e83, replyNumber=0, likeNumber=72, createdTime=2022-01-25, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286329456e83, moduleTitle=在需求激增的情况下，葛兰素史克和Vir提高了COVID-19抗体疗法Sotrovimab的产量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=286329456e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575866, encodeId=aeee15e586612, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=NEJM重磅：新型 IL-36 抗体疗法 spesolimab 可有效快速治疗泛发性脓疱型银屑病 (GPP) 急性发作, objectType=article, longId=292732, objectId=8da4292e32cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8da4292e32cb, replyNumber=0, likeNumber=70, createdTime=2021-12-26, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8da4292e32cb, moduleTitle=NEJM重磅：新型 IL-36 抗体疗法 spesolimab 可有效快速治疗泛发性脓疱型银屑病 (GPP) 急性发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8da4292e32cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575865, encodeId=056615e586590, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=君实生物JS016新冠双抗体疗法获得授权成为全球且唯一可在12岁以下人群中紧急使用的中和抗体疗法, objectType=article, longId=221620, objectId=04b3221620c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04b3221620c6, replyNumber=0, likeNumber=87, createdTime=2021-12-08, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04b3221620c6, moduleTitle=君实生物JS016新冠双抗体疗法获得授权成为全球且唯一可在12岁以下人群中紧急使用的中和抗体疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04b3221620c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575864, encodeId=f48515e5864ff, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=FDA授权礼来的COVID-19抗体疗法用于12岁以下儿童, objectType=article, longId=221611, objectId=90312216112f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90312216112f, replyNumber=0, likeNumber=102, createdTime=2021-12-08, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90312216112f, moduleTitle=FDA授权礼来的COVID-19抗体疗法用于12岁以下儿童, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90312216112f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575863, encodeId=e56515e58634d, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎, objectType=article, longId=214302, objectId=2dec214302a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dec214302a8, replyNumber=0, likeNumber=100, createdTime=2021-07-17, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dec214302a8, moduleTitle=NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dec214302a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575862, encodeId=054d15e586201, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=对变异毒株无效，礼来医药双抗体疗法被喊停, objectType=article, longId=213490, objectId=ba0b213490d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba0b213490d7, replyNumber=0, likeNumber=82, createdTime=2021-07-01, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba0b213490d7, moduleTitle=对变异毒株无效，礼来医药双抗体疗法被喊停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba0b213490d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575861, encodeId=4b4115e5861d6, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=君实生物回应抗体疗法，未来抗体疗法方向如何？, objectType=article, longId=213449, objectId=bc4f21344960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc4f21344960, replyNumber=0, likeNumber=101, createdTime=2021-06-30, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc4f21344960, moduleTitle=君实生物回应抗体疗法，未来抗体疗法方向如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc4f21344960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575860, encodeId=781315e586052, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=阿斯利康称其抗体疗法AZD7442预防有症状新冠肺炎效果未达主要目标, objectType=article, longId=212790, objectId=df31212e901a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df31212e901a, replyNumber=0, likeNumber=103, createdTime=2021-06-17, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df31212e901a, moduleTitle=阿斯利康称其抗体疗法AZD7442预防有症状新冠肺炎效果未达主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df31212e901a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575859, encodeId=204915e5859c3, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=礼来宣布，美国政府将购买更多剂量的中和抗体疗法来治疗COVID-19, objectType=article, longId=207696, objectId=f9c620e6964a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9c620e6964a, replyNumber=0, likeNumber=94, createdTime=2021-03-01, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9c620e6964a, moduleTitle=礼来宣布，美国政府将购买更多剂量的中和抗体疗法来治疗COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9c620e6964a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575858, encodeId=3a0515e585828, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, objectType=article, longId=205711, objectId=ced5205e1160, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced5205e1160, replyNumber=0, likeNumber=89, createdTime=2021-01-15, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced5205e1160, moduleTitle=礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced5205e1160)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575857, encodeId=bac015e58575e, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=Nat BME :集成方法可加快发现抗病毒抗体疗法的速度, objectType=article, longId=198846, objectId=505719884680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=505719884680, replyNumber=0, likeNumber=93, createdTime=2020-08-07, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=505719884680, moduleTitle=Nat BME :集成方法可加快发现抗病毒抗体疗法的速度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=505719884680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575856, encodeId=f7ef15e5856b1, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=Feinstein研究所收集COVID-19患者血浆，研究抗体疗法, objectType=article, longId=192018, objectId=a05b1920187a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a05b1920187a, replyNumber=0, likeNumber=73, createdTime=2020-04-13, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a05b1920187a, moduleTitle=Feinstein研究所收集COVID-19患者血浆，研究抗体疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a05b1920187a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575855, encodeId=2c0415e585565, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=抗击新冠在行动：Regeneron宣布与HHS扩大合作，开发针对新型冠状病毒的抗体疗法, objectType=article, longId=187513, objectId=217a18e513c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=217a18e513c4, replyNumber=0, likeNumber=83, createdTime=2020-02-07, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=217a18e513c4, moduleTitle=抗击新冠在行动：Regeneron宣布与HHS扩大合作，开发针对新型冠状病毒的抗体疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=217a18e513c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575854, encodeId=10d315e5854c8, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=SCIENCE：抗体疗法预防移植后巨细胞病毒的激活, objectType=article, longId=158493, objectId=2868158493cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2868158493cd, replyNumber=0, likeNumber=95, createdTime=2019-01-22, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2868158493cd, moduleTitle=SCIENCE：抗体疗法预防移植后巨细胞病毒的激活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2868158493cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575853, encodeId=f87c15e58536a, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=如何利用多种抗体疗法来攻克癌症及艾滋病？, objectType=article, longId=97018, objectId=c13b9e018d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c13b9e018d1, replyNumber=0, likeNumber=83, createdTime=2017-04-25, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c13b9e018d1, moduleTitle=如何利用多种抗体疗法来攻克癌症及艾滋病？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c13b9e018d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575852, encodeId=785915e585228, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=Nature：广谱的抗HIV中和抗体疗法优于抗HIV反转录的鸡尾酒疗法, objectType=article, longId=92046, objectId=56cc920468e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56cc920468e, replyNumber=0, likeNumber=74, createdTime=2017-03-18, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56cc920468e, moduleTitle=Nature：广谱的抗HIV中和抗体疗法优于抗HIV反转录的鸡尾酒疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56cc920468e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575851, encodeId=722d15e58515e, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=ASCO 2016：实验性的单克隆抗体疗法或有望治疗神经母细胞瘤, objectType=article, longId=69986, objectId=656169986a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=656169986a6, replyNumber=0, likeNumber=117, createdTime=2016-06-07, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=656169986a6, moduleTitle=ASCO 2016：实验性的单克隆抗体疗法或有望治疗神经母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=656169986a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575850, encodeId=492115e585078, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=Science两篇：抗体疗法有望治愈HIV, objectType=article, longId=67714, objectId=501c6e71477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=501c6e71477, replyNumber=0, likeNumber=97, createdTime=2016-05-09, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=501c6e71477, moduleTitle=Science两篇：抗体疗法有望治愈HIV, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=501c6e71477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1575849, encodeId=282815e5849de, content=<a href='/topic/show?id=118455194ad' target=_blank style='color:#2F92EE;'>#抗体疗法#</a>, objectTitle=一种双抗体疗法可治愈感染埃博拉的猴子, objectType=article, longId=64922, objectId=9ab364922af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ab364922af, replyNumber=0, likeNumber=73, createdTime=2016-03-18, rootId=0, userName=pps20024, userId=e8e216239493, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ab364922af, moduleTitle=一种双抗体疗法可治愈感染埃博拉的猴子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ab364922af)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗体疗法

2020-05-29

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

FDA授权礼来公司的第二个COVID-19抗体疗法bebtelovimab

2022-02-14

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

在需求激增的情况下，葛兰素史克和Vir提高了COVID-19抗体疗法Sotrovimab的产量

2022-01-25

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

NEJM重磅：新型 IL-36 抗体疗法 spesolimab 可有效快速治疗泛发性脓疱型银屑病 (GPP) 急性发作

2021-12-26

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

君实生物JS016新冠双抗体疗法获得授权成为全球且唯一可在12岁以下人群中紧急使用的中和抗体疗法

2021-12-08

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

FDA授权礼来的COVID-19抗体疗法用于12岁以下儿童

2021-12-08

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

NEJM：bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎

2021-07-17

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

对变异毒株无效，礼来医药双抗体疗法被喊停

2021-07-01

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

君实生物回应抗体疗法，未来抗体疗法方向如何？

2021-06-30

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

阿斯利康称其抗体疗法AZD7442预防有症状新冠肺炎效果未达主要目标

2021-06-17

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

礼来宣布，美国政府将购买更多剂量的中和抗体疗法来治疗COVID-19

2021-03-01

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

礼来阿尔茨海默病β淀粉样蛋白抗体疗法达到II期临床主要终点

2021-01-15

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

Nat BME :集成方法可加快发现抗病毒抗体疗法的速度

2020-08-07

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

Feinstein研究所收集COVID-19患者血浆，研究抗体疗法

2020-04-13

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

抗击新冠在行动：Regeneron宣布与HHS扩大合作，开发针对新型冠状病毒的抗体疗法

2020-02-07

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

SCIENCE：抗体疗法预防移植后巨细胞病毒的激活

2019-01-22

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

如何利用多种抗体疗法来攻克癌症及艾滋病？

2017-04-25

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

Nature：广谱的抗HIV中和抗体疗法优于抗HIV反转录的鸡尾酒疗法

2017-03-18

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

ASCO 2016：实验性的单克隆抗体疗法或有望治疗神经母细胞瘤

2016-06-07

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

Science两篇：抗体疗法有望治愈HIV

2016-05-09

pps20024 (审核中...)

前往app查看评论内容

#抗体疗法#

一种双抗体疗法可治愈感染埃博拉的猴子

2016-03-18

科室
- - 订阅+
  - 更多科室
工具
服务